AHCCCS
Pharmacy and Therapeutics Committee Meeting Minutes
May 17, 2016
12:00PM- 4:00 PM
701 E. Jefferson Phoenix, AZ  85034- Gold Room- 3rd Floor

Members Present:
Dan Lindell
Stephen Chakmakian
James Hargrave
Lydia Nesemann
Robert Marotz
Berkley Olvera
Cindy Komar
Gloria Abril
Shawn McMahon
Otto Uhrik
Kathleen Bryant
Suzanne Campbell
Mohamad Ramadan

AHCCCS Staff:
Sara Salek
Suzi Berman
Robin Davis
Lauren Prole
Kathy Bashor

Magellan Medicaid Admin:
Doug Brown
Rick Pope

Members via teleconference:
None

Members Absent:
Olivia Young
Joanna Kowalik
WELCOME AND INTRODUCTIONS: SARA SALEK, M.D., CHIEF MEDICAL OFFICER, AHCCCS

1. Dr. Sara Salek called the meeting to order at 12:00 PM and welcomed committee members, staff, and guest speakers.

AHCCCS and Behavioral Health Drug Lists

SUPPLEMENTAL REBATE CLASS REVIEW

1. Substance Use Disorder
   a. Clinical review: Provider Synergies – Doug Pope
   b. Pharma Testimony:
      i. Deborah Profant: Alkermes: Vivitrol
      ii. William Mullen: Indivior: Suboxone
      iii. Thomas Begres: Adapt Pharma: Narcan Nasal Spray
   c. Public Testimony:
      i. Michael Sucher
      ii. Lloyd Vacovsky
      iii. Doray Elkins
      iv. Kathleen Adams

2. Hepatitis C
   a. Clinical review: Provider Synergies  Rick Pope
   b. Pharma Testimony:
      i. Coleen Fong: Gilead: Harvoni
      ii. Laura Hill: Abbvie: Viekira Pak
      iii. John Michael Thomas: Bristol Myers Squibb: Daklinza
      iv. Ralph Gualtieri: Merck: Zepatier
   c. Public Testimony:
3. Hypoglycemics: Incretin Mimetics/Enhancers
   a. Clinical review: *Provider Synergies Dr. Pope*
   b. Pharma Testimony:
      i. Michele Jones: Novo Nordisk: Victoza
      ii. Ralph Gualtieri: Merck: Januvia
      iii. William O’Neill: Boehringer Ingelheim: Jardiance, Glyxambi, Tradjenta
   c. Public Testimony – None

4. Hypoglycemics: Insulin and Related Agents
   a. Clinical review: *Provider Synergies Rick Pope*
   b. Pharma Testimony
      i. Michele Jones: Novo Nordisk: Tresiba, Levemir, Novolog
      ii. Nana Numapau: Sanofi: Toujeo
   c. Public Testimony – None

5. COPD
   a. Clinical review: *Provider Synergies Rick Pope*
      i. William O’Neill (Boehringer Ingelheim) Spiriva, Stiolto
   b. Public Testimony – None

6. Executive Session -Closed to the public

7. Class Votes
   a. Opioid Dependence Treatment
      i. Committee members voted unanimously to add the following to the AHCCCS Drug List as preferred products. No members opposed or abstained.
         1. Naloxone vial and syringe
         2. Naloxone Nasal spray (Narcan)
         3. Naltrexone oral (ReVia)
         4. Naltrexone ER injectable suspension (Vivitrol)
            a. Remove PA
         5. Buprenorphine/naloxone sublingual film (Suboxone)
            a. Remove PA
            b. No Grandfathering
ii. Committee members voted unanimously to add the following to the AHCCCS Drug List as preferred products. No members opposed or abstained.
   1. Naloxone vial and syringe (solution for injection)
   2. Naloxone Nasal Spray (Narcan)

b. Hepatitis C Agents
   i. Committee members voted unanimously to add the following to the AHCCCS Drug List as preferred products. No members opposed or abstained.
      1. Peg-Intron
      2. Pegasys Vial, ProClick, Syringe
      3. Ribavirin tablet and capsule
      4. Zepatier
      5. Technivie
      6. Viekira
      7. Daklinza
      8. Harvoni (currently preferred)
      9. Sovaldi (currently preferred)

c. Hypoglycemics, Incretin Mimetics/Enhancers
   i. Committee members voted unanimously to add the following to the AHCCCS Drug List as preferred products with grandfathering in place for all except Bydureon pen. No members opposed or abstained.
      1. Janumet
      2. Janumet XR
      3. Januvia
      4. Jentadueto
      5. Tradjenta
      6. Byetta Pens
      7. Symlin Pens
      8. Victoza

d. Hypoglycemics, Insulin and Related Agents
   i. Committee members voted unanimously to add the following to the AHCCCS Drug List as preferred products with no grandfathering. PA status on pen products will be determined after further review. No members opposed or abstained.
      1. Humalog vial and pen
      2. Humalog mix vial and pen
      3. Humulin 70/30 vial
      4. Humulin vial
5. Humulin 500 U/M vial and pen
6. Levemir vial and pen
7. Lantus Solostar Pen
8. Lantus vial

e. COPD Agents
   i. Committee members voted unanimously to add the following to the AHCCCS Drug List as preferred products with no grandfathering. No members opposed or abstained.
      1. Ipratropium inhalation solution
      2. Ipratropium/albuterol inhalation solution
      3. Spiriva
      4. Atrovent HFA
      5. Combivent Respimat

APPROVAL OF FEBRUARY 2016 P&T MEETING MINUTES

1. Motion made by Lydia Nesemann to approve February 2016 meeting minutes
2. Motion seconded by Dr. Marotz
3. 10 committee members voted in favor of approving the minutes
4. 0 committee members opposed
5. 1 committee member abstained

HCV PRIOR AUTHORIZATION CRITERIA: SUZI BERMAN

The HCV PA Criteria is currently being revised and will be sent out for public comment.

NEW DRUG REVIEWS: NON-SUPPLEMENTAL REBATE CLASS: RICK POPE/SUZI BERMAN

1. Oncology:
   a. Recommendation made to form subcommittee to review oral oncology agents
      i. 8 committee members voted in favor
      ii. 0 committee members opposed
      iii. 3 committee members abstained
b. Alecensa
   i. Recommendation is to add Alecensa to the AHCCCS drug list with PA
      1. Motion made by Dr. Chakmakian to add Alecensa with PA
      2. Motion seconded by Dr. Marotz
      3. All committee members voted in favor of the motion
      4. No committee members opposed or abstained

c. Cotelllic
   i. Recommendation to add Cotelllic to the AHCCCS drug list with PA
      1. Motion made by Dr. Chakmakian to add Cotelllic with PA
      2. Motion seconded by Lydia Nesemann
      3. All committee members voted in favor of the motion
      4. No committee members opposed or abstained

d. Ninlaro
   i. Recommended to add Ninlaro to the AHCCCS drug list with PA
      1. Motion made by Dr. Chakmakian to add Ninlaro with PA
      2. Motion seconded by Dr. Marotz
      3. All committee members voted in favor of the motion
      4. No committee members opposed or abstained

e. Tagrisso
   i. Recommended to add Tagrisso to the AHCCCS drug list with PA
      1. Motion made by Dr. Chakmakian to table in order to research further
      2. Motion seconded by Kathleen Bryant
      3. All committee members voted in favor of the motion
      4. No committee members opposed or abstained

2. Aristada (LAI)
   a. Recommendation is to not add Aristada to the AHCCCS Drug List or the Behavioral Health Drug List and review the long-acting injectable atypical antipsychotics as a supplemental rebate therapeutic class after July 1st.
      i. Motion made by Kathleen Bryant to table until after July 1st
      ii. Motion seconded by Dr. Chakmakian
      iii. All committee members voted in favor of the motion
      iv. No committee members opposed or abstained

3. Belbuca (narcotic, long acting)
   a. Recommendation is to not add Belbuca to the AHCCCS Drug List because there are many other long-acting agents available that are more cost-effective.
i. Motion made by Dan Lindell to table and review entire class of Opioids for supplemental rebate
ii. Motion seconded by Dr. Ramadan
iii. All committee members voted in favor of the motion
iv. No committee members opposed or abstained

4. Dyanavel XR (stimulants)
   a. Recommendation is to not add Dyanavel XR to the AHCCCS Drug List or the Behavioral Health Drug List because there are other more cost effective stimulants available on these drug lists.
      i. Motion Made by Dr. Chakmakian to remain off of the AHCCCS Drug List
      ii. Motion seconded by Lydia Nesemann
      iii. All committee members voted in favor of the motion
      iv. No committee members opposed or abstained

5. Genvoya (HIV/AIDS)
   a. Recommendation is to add Genvoya to the AHCCCS Drug List with prior authorization.
      i. Motion made by Dan Lindell to add to the AHCCCS Drug list with no prior authorization
      ii. Motion seconded by Dr. Marotz
      iii. 5 committee members voted in favor of the motion
      iv. 0 committee members Opposed
      v. 6 committee members Abstained

6. Invega Trinza (LAI)
   a. Recommendation is not to add Invega Trinza to the AHCCCS drug list and review as a supplemental rebate therapeutic class after July 1st.
      i. Motion made by Kathleen Bryant to table and review entire class after July 1st.
      ii. Motion seconded by Lydia Nesemann
      iii. All committee members voted in favor of the motion
      iv. No committee members opposed or abstained

7. Keveyis (CAI)
   a. Recommendation to add Keveysis wot the AHCCCS drug list with prior authorization
      i. Motion made by Lydia Nesemann to leave off of the AHCCCS drug list as a non preferred agent and make available via PA only.
      ii. Motion seconded by Dr. Chakmakian
      iii. 10 committee members voted in favor of the motion
      iv. No committee members opposed
      v. 1 committee member abstained
8. Quillichew ER (stimulants)
   a. Recommended to not add Quillichew ER to the AHCCCS or Behavioral Health drug list because many other Methylphenidate products are more cost effective.
      i. Motion made by Dr. Chakmakian to leave off of the AHCCCS and Behavioral Health Drug lists.
      ii. Motion seconded by Kathleen Bryant
      iii. All committee members voted in favor of the motion
      iv. No committee members opposed or abstained

9. Uptravi (PAH)
   a. Recommended to not add Uptravi to the AHCCCS drug list as there are several other options currently available on the drug list.
      i. Motion made by Lydia Nesemann not to add Uptravi to the AHCCCS drug list
      ii. Motion seconded by Kathleen Bryant
      iii. All committee members voted in favor of the motion
      iv. No committee members abstained

10. Rexulti (antipsychotic/MDD)
    a. Recommendation is not to add Rexulti to the AHCCCS preferred drug list or the Behavioral Health drug list
       i. Motion made by Kathleen Bryant to table until after July 1st
       ii. Motion seconded by Dan Lindell
       iii. All committee members voted in favor of the motion
       iv. No committee members opposed or abstained

BIOLOGIC UPDATE: SUZI BERMAN

1. Glatopa (Biosimilar for Copaxone)
   a. Per the AHCCCS Medical Policy Manual: Policy 310V:
      i. AHCCCS Contractors shall not transition to a biosimilar drug until AHCCCS has determined that the biosimilar drug is overall more cost-effective to the state than the continued use of the brand name drug.
   b. AHCCCS and its contractors shall continue to cover only the brand name Copaxone because it is more cost effective than Glatopa.
P&T OPERATIONAL POLICY: SARA SALEK

Discussion Tabled until August 2017 P&T meeting

AGENDA ITEMS FOR AUGUST 16, 2016 P&T: ALL

Please email Suzi Berman any requests for agenda items for the August 2016 meeting.

ADJOURNMENT

The meeting adjourned at 5:20 PM
Minutes recorded by Robin Davis

Suzi Berman, RPh

Suzi Berman, RPh
Director of Pharmacy Services
AHCCCS

Date: August 16, 2016